Overview A Study With Imlifidase in Anti-GBM Disease Status: Recruiting Trial end date: 2026-11-01 Target enrollment: Participant gender: Summary An open-label, controlled, randomised, multi-centre Phase 3 trial evaluating renal function in patients with severe anti-GBM disease comparing imlifidase and standard of care (SoC) with SoC alone. All patients will remain in the trial for 24 months. Phase: Phase 3 Details Lead Sponsor: Hansa Biopharma ABTreatments: CyclophosphamideGlucocorticoids